An open label clinical trial of complement inhibition in multifocal motor neuropathy

Amanda M. Fitzpatrick, Cameron A. Mann, Sarah Barry, Katie Brennan, James R. Overell, Hugh J. Willison

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Human and animal studies on antibody-mediated neuropathy implicate complement in pathogenesis. In animal models complement inhibition is therapeutically beneficial. The monoclonal antibody, eculizumab (Soliris (TM), Alexion Pharmaceuticals, Cheshire, CT), prevents cleavage of C5 and thus inhibits terminal complement activation. In an open label study, 13 multifocal motor neuropathy patients received eculizumab for 14 weeks, 10 of whom were concomitantly receiving intravenous immunoglobulin. The primary outcome was safety of eculizumab, and the secondary outcomes included change in intravenous immunoglobulin (IVIg) dosing frequency, performance, and electrophysiological parameters. Adverse events were minor during the study. Nine of 10 patients on IVIg maintenance continued to require IVIg. IVIg dosing interval was not different between the run-in and the treatment period. There were improvements in patient-rated subjective scores and selected clinical and electrophysiological measurements. Overall, a small treatment effect occurred in some patients that appeared supplementary to and independent of the IVIg treatment effect, and occurred more frequently in patients with higher baseline motor function
LanguageEnglish
Pages84-91
Number of pages8
JournalJournal of the Peripheral Nervous System
Volume16
Issue number2
DOIs
Publication statusPublished - 21 Jun 2011

Fingerprint

Intravenous Immunoglobulins
Clinical Trials
Complement Activation
Therapeutics
Animal Models
Monoclonal Antibodies
Maintenance
Safety
eculizumab
Antibodies
Pharmaceutical Preparations

Keywords

  • clinical trial
  • complement
  • intravenous immunoglobulin
  • membrane attackcomplex
  • multifocal motor neuropathy
  • therapy

Cite this

Fitzpatrick, Amanda M. ; Mann, Cameron A. ; Barry, Sarah ; Brennan, Katie ; Overell, James R. ; Willison, Hugh J. / An open label clinical trial of complement inhibition in multifocal motor neuropathy. In: Journal of the Peripheral Nervous System. 2011 ; Vol. 16, No. 2. pp. 84-91.
@article{5ce13f0c5f2e4ccd9dfb77b862e6e84e,
title = "An open label clinical trial of complement inhibition in multifocal motor neuropathy",
abstract = "Human and animal studies on antibody-mediated neuropathy implicate complement in pathogenesis. In animal models complement inhibition is therapeutically beneficial. The monoclonal antibody, eculizumab (Soliris (TM), Alexion Pharmaceuticals, Cheshire, CT), prevents cleavage of C5 and thus inhibits terminal complement activation. In an open label study, 13 multifocal motor neuropathy patients received eculizumab for 14 weeks, 10 of whom were concomitantly receiving intravenous immunoglobulin. The primary outcome was safety of eculizumab, and the secondary outcomes included change in intravenous immunoglobulin (IVIg) dosing frequency, performance, and electrophysiological parameters. Adverse events were minor during the study. Nine of 10 patients on IVIg maintenance continued to require IVIg. IVIg dosing interval was not different between the run-in and the treatment period. There were improvements in patient-rated subjective scores and selected clinical and electrophysiological measurements. Overall, a small treatment effect occurred in some patients that appeared supplementary to and independent of the IVIg treatment effect, and occurred more frequently in patients with higher baseline motor function",
keywords = "clinical trial, complement, intravenous immunoglobulin, membrane attackcomplex, multifocal motor neuropathy, therapy",
author = "Fitzpatrick, {Amanda M.} and Mann, {Cameron A.} and Sarah Barry and Katie Brennan and Overell, {James R.} and Willison, {Hugh J.}",
year = "2011",
month = "6",
day = "21",
doi = "10.1111/j.1529-8027.2011.00328.x",
language = "English",
volume = "16",
pages = "84--91",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
number = "2",

}

An open label clinical trial of complement inhibition in multifocal motor neuropathy. / Fitzpatrick, Amanda M.; Mann, Cameron A.; Barry, Sarah; Brennan, Katie; Overell, James R.; Willison, Hugh J.

In: Journal of the Peripheral Nervous System, Vol. 16, No. 2, 21.06.2011, p. 84-91.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An open label clinical trial of complement inhibition in multifocal motor neuropathy

AU - Fitzpatrick, Amanda M.

AU - Mann, Cameron A.

AU - Barry, Sarah

AU - Brennan, Katie

AU - Overell, James R.

AU - Willison, Hugh J.

PY - 2011/6/21

Y1 - 2011/6/21

N2 - Human and animal studies on antibody-mediated neuropathy implicate complement in pathogenesis. In animal models complement inhibition is therapeutically beneficial. The monoclonal antibody, eculizumab (Soliris (TM), Alexion Pharmaceuticals, Cheshire, CT), prevents cleavage of C5 and thus inhibits terminal complement activation. In an open label study, 13 multifocal motor neuropathy patients received eculizumab for 14 weeks, 10 of whom were concomitantly receiving intravenous immunoglobulin. The primary outcome was safety of eculizumab, and the secondary outcomes included change in intravenous immunoglobulin (IVIg) dosing frequency, performance, and electrophysiological parameters. Adverse events were minor during the study. Nine of 10 patients on IVIg maintenance continued to require IVIg. IVIg dosing interval was not different between the run-in and the treatment period. There were improvements in patient-rated subjective scores and selected clinical and electrophysiological measurements. Overall, a small treatment effect occurred in some patients that appeared supplementary to and independent of the IVIg treatment effect, and occurred more frequently in patients with higher baseline motor function

AB - Human and animal studies on antibody-mediated neuropathy implicate complement in pathogenesis. In animal models complement inhibition is therapeutically beneficial. The monoclonal antibody, eculizumab (Soliris (TM), Alexion Pharmaceuticals, Cheshire, CT), prevents cleavage of C5 and thus inhibits terminal complement activation. In an open label study, 13 multifocal motor neuropathy patients received eculizumab for 14 weeks, 10 of whom were concomitantly receiving intravenous immunoglobulin. The primary outcome was safety of eculizumab, and the secondary outcomes included change in intravenous immunoglobulin (IVIg) dosing frequency, performance, and electrophysiological parameters. Adverse events were minor during the study. Nine of 10 patients on IVIg maintenance continued to require IVIg. IVIg dosing interval was not different between the run-in and the treatment period. There were improvements in patient-rated subjective scores and selected clinical and electrophysiological measurements. Overall, a small treatment effect occurred in some patients that appeared supplementary to and independent of the IVIg treatment effect, and occurred more frequently in patients with higher baseline motor function

KW - clinical trial

KW - complement

KW - intravenous immunoglobulin

KW - membrane attackcomplex

KW - multifocal motor neuropathy

KW - therapy

UR - http://eprints.gla.ac.uk/54017/

UR - https://onlinelibrary.wiley.com/journal/15298027

U2 - 10.1111/j.1529-8027.2011.00328.x

DO - 10.1111/j.1529-8027.2011.00328.x

M3 - Article

VL - 16

SP - 84

EP - 91

JO - Journal of the Peripheral Nervous System

T2 - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 2

ER -